Medicare sets preliminary payment rates for Cardio Diagnostics tests

Cardio Diagnostics Holdings (CDIO), a micro-cap diagnostics company, announced preliminary CMS gapfill payment rates of $350 for its Epi+Gen CHD test and $684.76 for its PrecisionCHD test, set to become effective January 1, 2025, pending finalization. This establishes a critical revenue stream for the company's key cardiovascular diagnostic products. Concurrently, CDIO is expanding its intellectual property with a new Japan patent for heart disease biomarkers and has initiated a clinical study with AGEPHA Pharma. However, the company also plans a 1-for-30 reverse stock split effective May 13, 2025, aimed at meeting Nasdaq's minimum bid price requirement.

Analysis

Cardio Diagnostics Holdings (CDIO), a micro-cap firm with a $7.6 million market valuation, has achieved a critical milestone with the Centers for Medicare and Medicaid Services (CMS) issuing preliminary gapfill payment rates for its core products. The proposed rates of $350 for the Epi+Gen CHD test and $684.76 for the PrecisionCHD test, set to be finalized later this year for a January 1, 2025 effective date, establish a foundational pathway for revenue generation from the Medicare market. This regulatory progress is complemented by strategic initiatives aimed at long-term value creation, including a new clinical study agreement with AGEPHA Pharma and the expansion of its intellectual property portfolio with a patent in Japan. However, these positive developments are juxtaposed with a significant corporate action: a 1-for-30 reverse stock split. This measure is being taken to comply with Nasdaq's minimum bid price requirement, a move that underscores the stock's persistent low price and the inherent risks of a micro-cap company, despite its operational advancements. The upcoming earnings announcement on August 14, 2025, will be a key data point for assessing the company's financial health post these developments.

Key Decisions for Investors

• Investors with a high risk tolerance may view the preliminary CMS payment rates as a significant de-risking event that validates the company's commercialization strategy and provides a line of sight to a future revenue stream.
• The planned 1-for-30 reverse stock split is a material red flag, and investors should consider that such actions are typically undertaken to avoid delisting and do not change the company's fundamental valuation or underlying business risks.
• It is prudent to monitor the finalization of the CMS payment rates later this year and to closely scrutinize the August 14, 2025 earnings report for early signs of commercial adoption and progress toward profitability.